Focus on breast cancer

Cancer Cell

Volumn 1, Issue 4, 2002, Pages 319-322

  Baselga, Jose ^a   Norton, Larry ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; CANCER GENETICS; CANCER THERAPY; DISEASE CLASSIFICATION; HUMAN; INCIDENCE; MAMMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; UNITED STATES; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

TUMOR MARKER; TUMOR PROTEIN;

BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; NEOPLASM PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0036562180     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00066-1     Document Type: Review

References (39)

1. Adams, J., Palombella, V., Sausville, E., Johnson, J., Destree, A., Lazarus, D., Maas, J., Pien, C., Prakash, S., and Elliott, P. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
2. AJCC (1997). Cancer Staging Manual, 5th Edition (Philadelphia: Lippincott-Raven).
3. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., et al. (2002). Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 ('Iressa') in skin from cancer patients: Histopathological and molecular consequences of receptor inhibition. J. Clin. Oncol. 20, 110-124.
4. Baselga, J., Norton, L., Albanell, J., Kim, Y.M., and Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831.
5. Baselga, J., Pfister, D., Cooper, M.R., Cohen, R., Burtness, M., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000). Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914.
6. Bier, H., Hoffmann, T., Hauser, U., Wink, M., Ochler, M., Kovar, A., Muser, M., and Knecht, R. (2001). Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 47, 519-524.
7. Chen, H.X., Marshall, J.L., Trocky, N., Ling, Y., Baidas, S., Rizvi, N., Bhargava, P., Lippman, M., Yang, D., and Hayes, D.F. (2000). A phase I study of BCL-2 Antisense G3139 (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Proc. Am. Soc. Clin. Onc. 19, A692.
8. Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the more randomized trial. JAMA 281, 2189-2197.
9. Czernin, J., and Phelps, M.E. (2001). Positron emission tomography scanning: Current and future applications. Annu. Rev. Med. 53, 89-112.
10. Dickson, R.B., and Lippman, M.E. (2001). Cancer of the Breast. Molecular Biology of Breast Cancer. In Principles and Practice of Oncology, V.T.J. DeVita, S. Hellman, and S. A. Rosenberg, eds. (Philadelphia: Lippincott Williams & Wilkins), pp. 1633-1645
11. EBCT. (1998a). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351, 1451-1467.
12. EBCT. (1998b). Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352, 930-942.
13. EBCT. (2000). Favourable and unfavourable effects on long-term survival of radiation therapy for early breast cancer: an overview of the randomized trials. Lancet 355, 1757-70.
14. Eisen, A., Rebbeck, T.R., Wood, W.C., and Weber, B.L. (2000). Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J. Clin. Oncol. 18, 1980-1995.
15. Elledge, R.M., and Fuqua, S.A.W. (2000). Estrogen and progesterone receptors. In Diseases of the Breast, J.R. Harris, M.E. Lippman, M. Morrow, and C.K. Osborne, eds. (Philadelphia: Lippincott Williams & Wilkins), pp. 471.
16. Feigelson, H.S., and Henderson, B.E. (2001). The epidemiology of breast cancer. In Breast cancer: A Clinical Guide to Therapy, G. Bonnadona, G.N. Hortobagyi, and A. M. Gianni, eds. (London: Martin Dunitz LTD.).
17. Fisher, B., Constantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel project P-1 study. J. Natl. Cancer Inst. 90, 1371-1388.
18. Gibbs, J.B. (2000). Mechanism-based target identification and drug discovery in cancer res. Science 287, 1969-1973.
19. Hortobagyi, G.N. (2000). Developments in chemotherapy of breast cancer. Cancer 88, 3073-3079.
20. Howe, H.L., Wingo, P.A., Thun M.J., Ries, L.A.G., Rosenberg, H.M., Feigal, E.G., and Edwards, B.K. (2001). Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst. 93, 824-842.
21. Ince, T.A., and Weinberg, R.A. (2002). Functional genomics and the breast cancer problem. Cancer Cell 1, 15-17.
22. Johnston, S., Ellis, P.A., Houston, S., Hickish, T., Howes, A.J., Palmer, P., and Horak, I. (2000). A Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Advanced Breast Cancer. Proc. Am. Soc. Clin. Onc. Ann. Mtg. 19, A318.
23. Jordan, V.C. (2001). Selective estrogen receptor modulation: A personal perspective. Cancer Res. 61, 5683-5687.
24. Kerlikowske, K. (1997). Efficacy of screening mamography among women aged 40 to 49 years and 50 to 60 years: comparison of relative and absolute benefit. J. Natl. Cancer Inst. Monogr. 22, 79-86.
25. Lyons, J.F., Wilhelm, S., Hibner, B., and Bollag, G. (2001). Discovery of a novel Raf Kinase inhibitor. Endocr. Relat. Cancer 8, 219-225.
26. Nabholtz, J.M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., and von Euler, M. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18, 3758-3767.
27. Nathanson, K.L., Wooster, R., and Weber, B.L. (2001). Breast cancer genetics: What we know and what we need. Nat. Med. 7, 552-556.
28. Norton, L. (2001). Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6 (suppl 3), 30-35.
29. Olsen, O., and Gotzsche, P. (2001). Cochrane review on screening for breast cancer with mammography. Lancet 358, 1340-1342.
30. Peto, R., Borecham, J., Clarke, M., Davies, C., and Beral, V. (2000). UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355, 1822.
31. Probst-Hensch, N.M., Pike, M.C., McKean-Cordin, R., Stanczyk, F.Z., Kolonel, L.N., and Henderson, B.E. (2000). Ethnic differences in post-menopausal plasma estrogen levels: high estrone levels in Japanese-American women despite low weight. Br. J. Cancer 82, 1867-1870.
32. Schwall, R.H., Dugger, D., Erickson, S.L., Yee, S., Phillips, G., Chari, R.V., and Sliwkowski, M.X. (2001). Potent preclinical efficacy of Herceptin-DM1 against HER2-overexpresing breast tumors in vivo. In 12th NCI-AACR-EORTC Meeting. (Miami, FL.), p. A652.
33. Sebolt-Leopold, J.S. (2001). CI-1040: a novel small molecule MEK inhibitor with broad spectrum antitumor activity. In 12th NCI-AACR-EORTC Meeting. (Miami, FL.), p. 818.
34. Senderowicz, A.M. (2000). Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19, 6600-6606.
35. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Concurrent administration of anti-HER-2 monoclonal antibody and first-line chemotherapy for HER2-overexpresing metastatic breast cancer: A phase III, multinational, randomized, conrolled trial. N. Engl. J. Med. 344, 783-792.
36. Sledge, G., Miller, K., Novotny, W., Gaudreault, J., Ash, M., and Cobleigh, M. (2000). A phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Onc. 19, A5.
37. Stoutjesdijk, M.J., Boetes, C., Jager, G.J., Beex, L., Bult, P., Hendriks, J.H., Laheij, R.J., Massuger, L., van Die, L.E., Wobbes, T., and Barentsz, J.O. (2001). Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J. Natl. Cancer Inst. 93, 1095-1102.
38. van't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., and Friend, S.H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
39. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W.-G., Skotnicki, J., Frost, P., and Gibbons, J.J. (2001). mTor, a novel target in breast caner: the effect of CCI-779, an m-TOR inhbitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8, 249-258.